UB TT170
Alternative Names: ex vivo TagCAR T cells - Umoja Biopharma; TumorTag UB-TT170 - Umoja Biopharma; UB TT170 with ex vivo TagCAR T cells - Umoja BiopharmaLatest Information Update: 23 May 2023
At a glance
- Originator Umoja Biopharma
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies; Small molecules
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Osteosarcoma
- Preclinical Solid tumours
Most Recent Events
- 17 May 2023 Pharmacodynamics data from preclinical trial in solid tumours released by Umoja Biopharma
- 11 Oct 2022 Phase-I clinical trials in Osteosarcoma (In adolescents, In adults, In children, Recurrent, Second-line therapy or greater) in USA (IV)(Umoja pipeline; October 2022)
- 01 Sep 2021 Preclinical trials in Osteosarcoma in USA (IV) as at September 2021 (Umoja Biopharma pipeline, September 2021)